论文部分内容阅读
从2003年–2007年,将同期入院的69例晚期癌症患者随机分为联合宜利治组及化疗组,观察食欲改善情况、恶心呕吐反应及KPS评分指标。联合组食欲有反应84.3%(27/32),而对照组59.5%(22/37),组间比较差异有显著性(P<0.01)。联合组恶心呕吐无反应68.7%(22/32),对照组47.5%(17/37),组间比较差异有显著性(P<0.01);KPS评分增加10分56.2%(18/32),对照组18.9%(7/37),组间比较差异有显著性(P<0.01)。甲地孕酮提高恶性肿瘤患者化疗期的耐受性有较好疗效。
From 2003 to 2007, 69 patients with advanced cancer who were hospitalized in the same period were randomly divided into combined Yili group and chemotherapy group. The improvement of appetite, nausea and vomiting response and KPS score were observed. In the combined group, the appetite was 84.3% (27/32) in the control group and 59.5% (22/37) in the control group, with significant difference between the two groups (P <0.01). In the combined group, 68.7% (22/32) were non-responsive and 47.5% (17/37) in the control group, with significant difference between the two groups (P <0.01); KPS score increased by 10 points and 56.2% (18/32) The control group 18.9% (7/37), the difference between the groups was significant (P <0.01). Megestrol to improve the tolerance of patients with malignant tumor chemotherapy has a good effect.